苯乙胺,3,4-二氯-N-甲基-N-[(1R,2S)-2-(1-吡咯烷基)环己基]- | 130609-94-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苯乙胺,3,4-二氯-N-甲基-N-[(1R,2S)-2-(1-吡咯烷基)环己基]-
• 英文名称: (1R,2S)-cis-N-<2-(3,4-dichlorophenyl)ethyl>-N-methyl-2-(1-pyrrolidinyl)cyclohexylamine
• 英文别名: (+)-cis-N-methyl-N-[2-(3,4-dichlorophenyl) ethyl]-2-(1-pyrrolidinyl) cyclohexylamine；1R,2S-(+)-cis-N-methyl-N-<2-(3,4-dichlorophenyl)ethyl>-2-(1-pyrrolidinyl)cyclohexylamine；BD-737；1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)cyclohexylamine；2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)cyclohexylamine；BD738；(1R,2S)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-pyrrolidin-1-ylcyclohexan-1-amine
• CAS: 130609-94-8
• 化学式: C₁₉H₂₈Cl₂N₂
• 分子量: 355.351
• InChiKey: SRRUPDPTTGLICG-MOPGFXCFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  U 50488 在 aluminium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 生成 苯乙胺,3,4-二氯-N-甲基-N-[(1R,2S)-2-(1-吡咯烷基)环己基]-
  参考文献：
  名称：

  高亲和力西格玛受体配体的N-取代的顺式-N-甲基-2-（1-吡咯烷基）环己胺的合成与评价。鉴定出新型的高效和选择性sigma受体探针。

  摘要：

  最近报道某些苯乙酰胺[（-）-和（+）-顺-3,4-二氯-N-甲基-N- [2-（1-吡咯烷基）环己基]苯乙酰胺]是有效的σ受体配体。为了确定是否可以提高对sigma受体的功效，合成了一系列与苯乙酰胺有关的化合物N-取代的顺式-2-（1-吡咯烷基）-N-甲基环己胺，并确定了其结构活性的要求。通过从先前报道的（+/-）-，1S，2R-（+）-和1R，2S-（-）-顺-2-（1-吡咯烷基）-N-甲基环己胺开始合成化合物。σ（[3H]（+）-3-PPP），kappa（[3H] bremazocine和[3H] U69,593），多巴胺-d2（[3H]（-）-舒必利）和苯环利定（PCP）的分析（[3H] TCP）受体在豚鼠脑中的结合揭示了许多高效和选择性的sigma受体配体。值得注意的是，1S，2R-顺-（-）-N-甲基-N- [2-（1-吡咯烷基）环己基]-（2-萘基）乙酰胺[（-）-29]（Ki

  DOI：

  10.1021/jm00173a030

文献信息

• Aralkyl diaxabicycloalkane derivatives for CNS disorders
  申请人：——

  公开号：US20020045624A1

  公开（公告）日：2002-04-18

  Certain aralkl diazabicycloalkyl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: 1 wherein each of R 1 , R 4 , R 5 , R 6 and R 7 is independently selected from hydrido, lower alkyl, benzyl, and haloloweralkyl; wherein each of R 2 , R 3 and R 8 through R 11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenols, benzyloxy and haloloweralkyl; wherein n is an integer of from four to six; wherein m is an integer of from two to four; wherein A is selected from phenyl, naphthyl, benzothienyl, benzofuranyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.

  本文描述了某些阿拉克尔二氮杂双环烷化合物，用于治疗中枢神经系统疾病，如脑缺血、精神病和抽搐。特别感兴趣的化合物的公式为：1其中R1、R4、R5、R6和R7中的每一个独立选择自氢、低级烷基、苯甲基和卤代低级烷基；其中R2、R3和R8至R11中的每一个独立选择自氢、羟基、低级烷基、苯甲基、酚、苯氧基和卤代低级烷基；其中n为4至6的整数；其中m为2至4的整数；其中A选择自苯基、萘基、苯并噻吩基、苯并呋喃基和噻吩基；其中任何上述A基团都可以进一步用一个或多个取代基独立选择自氢、羟基、低级烷基、低级烷氧基、卤素、卤代低级烷基、氨基、单低级烷基氨基和双低级烷基氨基取代；或其药学上可接受的盐。
• Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for CNS
  申请人：G. D. Searle & Co.

  公开号：US05130330A1

  公开（公告）日：1992-07-14

  Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychotic disorders and convulsions. Compounds of particular interest are of the formula ##STR1## wherein R.sup.1 is selected from hydrido, loweralkyl, cycloalkylalkyl of four to six carbon atoms, and loweralkenylloweralkyl; wherein each of R.sup.2 and R.sup.3 is independently selected from hydrido and loweralkyl; wherein each of R.sup.4 through R.sup.7, R.sup.10 and R.sup.11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is a number selected from four through six; wherein p is a number selected from zero through four; wherein q is a number selected from three through five; wherein A is selected from phenyl, naphthyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.

  本文描述了一些含氮的环杂环烷基氨基芳基化合物，用于治疗中枢神经系统疾病，如脑缺血、精神障碍和癫痫。特别感兴趣的化合物为下式：##STR1##其中R1选自氢、低碳基、四至六个碳原子的环烷基烷基和低碳烯基烷基；其中R2和R3各自独立地选自氢和低碳基；其中R4至R7、R10和R11各自独立地选自氢、羟基、低碳基、苄基、苯氧基、苄氧基和卤代低碳基；其中n为4至6的数字；其中p为0至4之间的数字；其中q为3至5之间的数字；其中A选自苯基、萘基和噻吩基；其中上述任何A基团都可以进一步用一个或多个取代基独立地选自氢、羟基、低碳基、低碳氧基、卤素、卤代低碳基、氨基、单低碳基氨基和双低碳基氨基取代；或其药学上可接受的盐。
• Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
  申请人：Köster Hubert

  公开号：US20110118136A1

  公开（公告）日：2011-05-19

  Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Each compound has the formula: wherein: Z is a trityl derivative; X, the reactivity function, covalently binds to amino acid side chains of proteins; Y, the selectivity function, modulates binding of X to the amino acid side chains in proteins such that X binds to fewer proteins when Y is present than in its absence; and Q permits separation or immobilization of the capture compound. Automated systems for performing the methods also are provided.

  本文提供了捕获化合物和化合物集合以及使用这些化合物进行生物分子分析的方法。特别地，提供了用于分析复杂蛋白质混合物（如蛋白质组）的集合、化合物和方法。这些化合物是多功能试剂，可用于分离和分离复杂蛋白质混合物。每个化合物的公式为：其中：Z是三苯甲基衍生物；X是反应性功能，共价结合到蛋白质的氨基酸侧链上；Y是选择性功能，调节X与蛋白质中氨基酸侧链的结合，使得在Y存在时，X与较少的蛋白质结合，而在Y不存在时，X与更多的蛋白质结合；Q允许分离或固定捕获化合物。本文还提供了用于执行这些方法的自动化系统。
• Compositions and methods for reversal of drug resistance
  申请人：——

  公开号：US20040224907A1

  公开（公告）日：2004-11-11

  The present invention relates to sigma-1 receptor ligands, to uses of sigma-1 receptor ligands in treating drug resistance, methods of using sigma-1 receptor ligands in regulating P-glycoprotein expression, methods of screening for compositions (e.g., agonists) that activate the sigma-1 receptor, regulate P-glycoprotein expression and/or have tolerance reducing activity.

  本发明涉及σ-1受体配体、σ-1受体配体在治疗耐药性中的用途、使用σ-1受体配体调节P-糖蛋白表达的方法、筛选激活σ-1受体、调节P-糖蛋白表达和/或具有耐受性降低活性的组合物（如激动剂）的方法。
• NITROGEN-CONTAINING CYCLOHETERO CYCLOALKYLAMINOARYL DERIVATIVES FOR CNS DISORDERS
  申请人：G.D. Searle & Co.

  公开号：EP0594597A1

  公开（公告）日：1994-05-04